As of January 22, 2025, Kyverna Therapeutics (KYTX) has a market cap of $0.14 billion USD. According to our data, Kyverna Therapeutics is ranked No.7417 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.14 B |
-12.03%
|
Dec 31, 2024 | $0.16 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Beam Therapeutics
BEAM
|
$2.19 B |
0.000 M
|
USA
|
Sana Biotechnology
SANA
|
$0.78 B |
0.000 M
|
USA
|
Precision BioSciences
DTIL
|
$38.13 M |
0.000 M
|
USA
|
Poseida Therapeutics
PSTX
|
$0.93 B |
0.000 M
|
USA
|
Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
Iovance Biotherapeutics
IOVA
|
$1.83 B |
-0.000 M
|
USA
|
Atara Biotherapeutics
ATRA
|
$39.68 M |
0.000 M
|
USA
|
Market Cap | = | KYTX Stock Price | * | KYTX Shares Outstanding |
= | $3.29 | * | 43.17 M | |
= | $0.14 B |